Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof

US11530229B2 · kind B2 · utility

Assignee

• NURIX THERAPEUTICS, INC. · US

Inventors

• Arthur Sands · Diemelstraße, US
• Neil F. Bence · Belmont, US
• Christoph Wolfgang Zapf · San Francisco, US
• Frederick Cohen · San Francisco, US
• Chenbo Wang · San Francisco, US
• Thomas J. Cummins · Rochester, US
• Hiroko Tanaka · Foster City, US
• Hunter Paul Shunatona · Oakland, US
• Mario Cardozo · San Francisco, US
• Dahlia Weiss · San Mateo, US
• Jennifa Gosling · San Francisco, US

Key dates

• Filing date: May 15, 2020
• Grant date: Dec 20, 2022
• Expiry date: May 28, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/08
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.